AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9296416 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine
Number of subjects: 102
Study 9296416 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA meperidine
Number of subjects: 102
Study 9296416 — intervention group
Group type: COMPARATOR
Intervention: Control (bottle-fed infants)
Number of subjects: 102
Study 8101046 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine
Number of subjects: 37
Study 8101046 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 37
Study 3797105 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma L-phenylalanine
Number of subjects: 8
Study 3797105 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased plasma L-phenylalanine
Number of subjects: 8
Study 31733181 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 145
Study 31733181 — intervention group
Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 145
Study 29882228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitions Questionnaire‐30 (MCQ‐30)
Number of subjects: 185
Study 26903605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional pentamidine (120 μg/mm² lesion area, 3 injections over 5 days)
Number of subjects: 150
Study 26903605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional pentamidine (240 μg/mm², 3 injections)
Number of subjects: 150
Study 26903605 — intervention group
Group type: COMPARATOR
Intervention: Intralesional therapy with antimony (3 injections over 5 days)
Number of subjects: 150
Study 26903605 — intervention group
Group type: COMPARATOR
Intervention: Intralesional therapy with antimony (5 injections over 11 days)
Number of subjects: 150
Study 26903605 — intervention group
Group type: COMPARATOR
Intervention: Intralesional therapy with antimony (5 injections)
Number of subjects: 150
Study 25175935 — intervention group
Group type: EXPERIMENTAL
Intervention: Um RSA
Number of subjects: 50
Study 25175935 — intervention group
Group type: EXPERIMENTAL
Intervention: RSAcore
Number of subjects: 50
Study 25175935 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary geometrical shape RSA
Number of subjects: 50
Study 25175935 — intervention group
Group type: COMPARATOR
Intervention: Marker-based RSA
Number of subjects: 50
Study 22901986 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil diet
Number of subjects: 24
Study 22901986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil diet
Number of subjects: 24
Study 22901986 — intervention group
Group type: COMPARATOR
Intervention: Palm oil diet
Number of subjects: 24
Study 20042934 — intervention group
Group type: EXPERIMENTAL
Intervention: Online counseling intervention (experimental group)
Number of subjects: 79
Study 20042934 — intervention group
Group type: COMPARATOR
Intervention: Control group (access to Internet-ready computer and 1 year of Internet service without online counseling)
Number of subjects: 79
Study 18287130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 mcg once daily
Number of subjects: 16
Study 18287130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15947223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus
Number of subjects: 30
Study 15947223 — intervention group
Group type: COMPARATOR
Intervention: Intact
Number of subjects: 30
Study 15200038 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal treatment (n = 52)
Number of subjects: 89
Study 15200038 — intervention group
Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate ointment (n = 37)
Number of subjects: 89
Study 11346391 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 420
Study 11346391 — intervention group
Group type: COMPARATOR
Intervention: Tap/Biopsy
Number of subjects: 420
Study 9209220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate 50 mg/kg
Number of subjects: 600
Study 9209220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 7959548 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion (perioperatively)
Number of subjects: 644
Study 7959548 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 644
Study 7959548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused patients
Number of subjects: 644
Study 3115667 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary copying of stimulated breathing pattern
Number of subjects: 6
Study 3115667 — intervention group
Group type: COMPARATOR
Intervention: Stimulated breathing
Number of subjects: 6
Study 31971952 — intervention group
Group type: EXPERIMENTAL
Intervention: Educore intervention (informative intervention arm)
Number of subjects: 411
Study 31971952 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 411
Study 29454389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention using intervention mapping (IM) framework with five educational modules and technical assistance calls
Number of subjects: 50
Study 29454389 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 27430394 — intervention group
Group type: EXPERIMENTAL
Intervention: Anma therapy (Japanese massage, AMT), 40-min session per week for 8 weeks
Number of subjects: 40
Study 27430394 — intervention group
Group type: COMPARATOR
Intervention: No AMT (control group)
Number of subjects: 40
Study 27430394 — intervention group
Group type: EXPERIMENTAL
Intervention: Anma therapy (Japanese massage, AMT), single session
Number of subjects: 40
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise during chemotherapy (n = 78)
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise during chemotherapy (n = 82)
Number of subjects: 242
Study 24633595 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 82)
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (exercise groups combined)
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant DFS (exercise groups combined)
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence-free interval (exercise groups combined)
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for overweight/obese women
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for stage II/III cancer
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for estrogen receptor-positive tumors
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for HER2-positive tumors
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for taxane-based chemotherapies
Number of subjects: 242
Study 24633595 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for patients receiving ≥85% of planned chemotherapy
Number of subjects: 242
Study 22533660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with SBP target <130 mm Hg
Number of subjects: 43
Study 22533660 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with SBP target <140 mm Hg
Number of subjects: 43
Study 22533660 — intervention group
Group type: COMPARATOR
Intervention: Normotensive individuals
Number of subjects: 43
Study 21109302 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (mainly atorvastatin 24 mg per day)
Number of subjects: 437
Study 21109302 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no statin treatment)
Number of subjects: 437
Study 21109302 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (mainly atorvastatin)
Number of subjects: 437
Study 18221430 — intervention group
Group type: EXPERIMENTAL
Intervention: CoZmonitor Blood Glucose Module
Number of subjects: 34
Study 18221430 — intervention group
Group type: COMPARATOR
Intervention: FreeStyle Flash meter (Control)
Number of subjects: 34
Study 16463007 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg daily (men and premenopausal women) / 10 mg daily (postmenopausal women)
Number of subjects: 163
Study 16463007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 16463007 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg daily / 10 mg daily
Number of subjects: 163
Study 12651757 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Number of subjects: 112
Study 12651757 — intervention group
Group type: COMPARATOR
Intervention: pMDI connected to Nebuhaler spacer with terbutaline sulphate (0.5 mg/10 kg, maximum 2.0 mg)
Number of subjects: 112
Study 12651757 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler and pMDI+Nebuhaler
Number of subjects: 112
Study 10917257 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio biofeedback
Number of subjects: 6
Study 10917257 — intervention group
Group type: COMPARATOR
Intervention: Conventional bathroom scale method (without audio biofeedback)
Number of subjects: 6
Study 8866702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB, 15 mg/kg
Number of subjects: 8
Study 8866702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB, 30 mg/kg
Number of subjects: 8
Study 8866702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8866702 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (both dosages)
Number of subjects: 8
Study 1502480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg or 800 mg)
Number of subjects: 25
Study 1502480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30415039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki‐67 labeling index
Number of subjects: 0
Study 30415039 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical cytocolorimetric index (ICI)
Number of subjects: 0
Study 30415039 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ICI values with time before relapse
Number of subjects: 0
Study 28114204 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA) peels combined with a modified Kligman formula (MKF) containing hydroquinone 2%, tretinoin 0.05%, and hydrocortisone 1%
Number of subjects: 30
Study 28114204 — intervention group
Group type: COMPARATOR
Intervention: Modified Kligman formula (MKF) alone
Number of subjects: 30
Study 25773149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) 20,000 IU/week
Number of subjects: 0
Study 25773149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24515923 — intervention group
Group type: EXPERIMENTAL
Intervention: Anklebot training
Number of subjects: 34
Study 24515923 — intervention group
Group type: COMPARATOR
Intervention: Passive manual stretching
Number of subjects: 34
Study 23067363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels in chronic hepatitis C (TNF‐α, IL‐10, IL‐18)
Number of subjects: 100
Study 23067363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels in chronic hepatitis B (IL‐10)
Number of subjects: 100
Study 23067363 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TNF‐α with Ishak score or fibrosis in CHB and CHC
Number of subjects: 100
Study 23067363 — intervention group
Group type: COMPARATOR
Intervention: Cytokine levels in control group
Number of subjects: 100
Study 20234783 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus amlodipine 5 mg
Number of subjects: 221
Study 20234783 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg plus amlodipine 5 mg
Number of subjects: 221
Study 20234783 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy
Number of subjects: 221
Study 18092240 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatekeeper training programme in 32 schools
Number of subjects: 0
Study 18092240 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based preventive interventions
Number of subjects: 0
Study 15903360 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine alone (Cr)
Number of subjects: 10
Study 15903360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined creatine and carbohydrate (Cr + CHO)
Number of subjects: 10
Study 12209034 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg
Number of subjects: 1088
Study 12209034 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 1088
Study 12209034 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 1088
Study 12209034 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 1088
Study 12209034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study 9796796 — intervention group
Group type: EXPERIMENTAL
Intervention: Interior design alternatives of a high-speed train
Number of subjects: 0
Study 7609111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic surgical system
Number of subjects: 16
Study 7609111 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adrenalectomy without ultrasonic surgical system
Number of subjects: 16
Study 2236453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 372
Study 2236453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 372
Study 2236453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 372
Study 2236453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 636967 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 4
Study 636967 — intervention group
Group type: COMPARATOR
Intervention: Mirror feedback
Number of subjects: 4
Study 31122600 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (POST)
Number of subjects: 143
Study 31122600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (POST2)
Number of subjects: 143
Study 31122600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 27979038 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow‐derived ALDHbr stem cells
Number of subjects: 82
Study 27979038 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 82
Study 25769960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai-chi group-based exercise program (60 minutes, twice weekly for 48 weeks)
Number of subjects: 503
Study 25769960 — intervention group
Group type: COMPARATOR
Intervention: Seated group-based flexibility exercise program (control)
Number of subjects: 503
Study 23761102 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 2‐2 genotype
Number of subjects: 1303
Study 23761102 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 1303
Study 23761102 — intervention group
Group type: COMPARATOR
Intervention: HP 2‐1 and 1‐1 genotypes
Number of subjects: 1303
Study 22118002 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide combined with bortezomib-dexamethasone (TBD)
Number of subjects: 46
Study 22118002 — intervention group
Group type: COMPARATOR
Intervention: Vincristine-doxorubicin-dexamethasone (T-VAD)
Number of subjects: 46
Study 19620850 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg once daily at night for 12 weeks
Number of subjects: 5
Study 19620850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 16399263 — intervention group
Group type: EXPERIMENTAL
Intervention: Related prime (e.g. 'piano')
Number of subjects: 0
Study 16399263 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual display with auditory input
Number of subjects: 0
Study 15546515 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual outreach group (joint teleconsultation via videolink)
Number of subjects: 2094
Study 15546515 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient appointments
Number of subjects: 2094
Study 15546515 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual outreach group
Number of subjects: 2094
Study 10907154 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct parental education (DPE) - 10 sessions
Number of subjects: 47
Study 10907154 — intervention group
Group type: EXPERIMENTAL
Intervention: Video parental education (VPE) - standardized video education at home
Number of subjects: 47
Study 10907154 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - dermatological standard treatment
Number of subjects: 47
Study 9310109 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltenac gel
Number of subjects: 290
Study 9310109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac
Number of subjects: 290
Study 9310109 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 290
Study 8376682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral milrinone with converting enzyme inhibitors
Number of subjects: 254
Study 3795265 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 0
Study 3795265 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification intervention
Number of subjects: 0
Study 3795265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 0
Study 3795265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30073496 — intervention group
Group type: EXPERIMENTAL
Intervention: Long biliopancreatic limb Roux-en-Y gastric bypass (LBP-GB) with BPL 150 cm, alimentary limb 75 cm
Number of subjects: 146
Study 30073496 — intervention group
Group type: COMPARATOR
Intervention: Standard Roux-en-Y gastric bypass (S-GB) with BPL 75 cm, alimentary limb 150 cm
Number of subjects: 146
Study 27473306 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) influenza vaccine
Number of subjects: 105
Study 27473306 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) influenza vaccine
Number of subjects: 105
Study 25636721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight exposure
Number of subjects: 566
Study 25636721 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured as hours/day)
Number of subjects: 566
Study 25636721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting (measured as hours/day)
Number of subjects: 566
Study 25636721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of fish
Number of subjects: 566
Study 25636721 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement intake
Number of subjects: 566
Study 23972968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg QD
Number of subjects: 5041
Study 23972968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5041
Study 21910510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 240 mg (fed state)
Number of subjects: 40
Study 21910510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 20-480 mg (fasted single doses)
Number of subjects: 40
Study 21910510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg (fasted repeated doses)
Number of subjects: 40
Study 21910510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 360 mg (fasted repeated doses)
Number of subjects: 40
Study 21910510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (various doses)
Number of subjects: 40
Study 21910510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (240 mg in fed state)
Number of subjects: 40
Study 21910510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18164612 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL172
Number of subjects: 96
Study 18164612 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus SRL172
Number of subjects: 96
Study 18164612 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 96
Study 18164612 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 96
Study 16923246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antioxidant supplementation (nutritional doses)
Number of subjects: 0
Study 16923246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 12654439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103 (125 Gy)
Number of subjects: 220
Study 12654439 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 (144 Gy)
Number of subjects: 220
Study 12654439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103 (90 Gy) with 44 Gy EBRT
Number of subjects: 220
Study 12654439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103 (115 Gy) with 20 Gy EBRT
Number of subjects: 220
Study 12654439 — intervention group
Group type: COMPARATOR
Intervention: Beam radiation (44 Gy)
Number of subjects: 220
Study 12654439 — intervention group
Group type: COMPARATOR
Intervention: Beam radiation (20 Gy)
Number of subjects: 220
Study 12654439 — intervention group
Group type: COMPARATOR
Intervention: Beam radiation
Number of subjects: 220
Study 12654439 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose Pd-103
Number of subjects: 220
Study 12654439 — intervention group
Group type: EXPERIMENTAL
Intervention: No instances of rectal ulceration or fistula reported
Number of subjects: 220
Study 10600654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (70 microg/min)
Number of subjects: 20
Study 10600654 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (5 mg/kg body weight)
Number of subjects: 20
Study 9170400 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 631
Study 9170400 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 631
Study 9170400 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 631
Study 1301267 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol mucilage (PM)
Number of subjects: 1705
Study 1301267 — intervention group
Group type: COMPARATOR
Intervention: Phenol-atabrine paste (PAP)
Number of subjects: 1705
Study 3942496 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of antibiotics
Number of subjects: 116
Study 3942496 — intervention group
Group type: COMPARATOR
Intervention: 5 days of antibiotics
Number of subjects: 116